Fulcrum Therapeutics (FULC) Non-Current Debt (2018 - 2021)

Fulcrum Therapeutics (FULC) has 4 years of Non-Current Debt data on file, last reported at $2.6 million in Q4 2021.

• On a quarterly basis, Non-Current Debt fell 15.37% year-over-year to $2.6 million in Q4 2021; TTM through Dec 2021 was $2.6 million, a 15.37% decrease from a year earlier, with the FY2021 full-year figure at $2.6 million, down 15.37% from the prior year.
• Non-Current Debt for Q4 2021 stood at $2.6 million, down from $2.7 million in the prior quarter.
• Over the last five years, Non-Current Debt for FULC reached as high as $4.0 million in Q4 2018 and fell as low as $2.6 million in Q4 2021.
• Historically, Non-Current Debt has averaged $3.2 million across 4 years, with a median of $3.2 million in 2020.
• Across the five-year window, Non-Current Debt slipped 11.75% in 2019 and fell 15.37% in 2021, its largest moves.
• Year by year, Non-Current Debt stood at $4.0 million in 2018, then fell by 11.75% to $3.5 million in 2019, then dropped by 13.35% to $3.1 million in 2020, then decreased by 15.37% to $2.6 million in 2021.
• Per Business Quant data, the three most recent Non-Current Debt figures were $2.6 million in Q4 2021, $2.7 million in Q3 2021, and $2.8 million in Q2 2021.